Regeneron Pharmaceuticals News

I have jokingly referred to Amgen, Inc. in the past as a "senior citizen" of biotech.

A novel approach to obstructing the runaway inflammatory response implicated in some types of asthma has shown promise in a Phase IIa clinical trial, according to U. S. researchers.

Human clinical trials show exciting promise for a new drug treatment for moderate and severe asthma, with further potential in treating severe eczema.

The firm currently has a "buy" rating on the stock. Shares of Regeneron Pharms traded up 0.95% during mid-day trading on Wednesday, hitting $262.42. Regeneron Pharms has a 52 week low of $107.31 and a 52 week high of $220.43. The stock's 50-day moving average is currently $186.. The company has a market cap of $25.422 billion and a P/E ratio of ... (more)

Shares of Regeneron Pharmaceuticals, Inc. have been dazzling investors by soaring to new all-time highs that are approaching $300 per share.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! When the US biotech company Regeneron Pharmaceuticals recently announced its first-quarter results, few were surprised that the company's flagship wet age-related macular degeneration product Eylea had once again exceeded consensus expectations.

Brian is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

Pharmaceutical names dominated the S&P 500's leaderboard with Bristol-Myers Squibb Co.

Phase 2a study of the IL-4R alpha inhibitor, dupilumab, demonstrated 87% reduction in risk of asthma exacerbations in moderate-to-severe asthma patients with elevated eosinophils Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine Phase 2a study of the IL-4R alpha ... (more)

A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.

Good morning, everybody. I'm Matthew Harrison, one of the Biotech analysts here at UBS.

Amgen shares have had an impressive run this year, outpacing the S&P 500 by about 6%. Nevertheless, despite outpacing the broader market, Amgen has only matched the Health Care Sector Select Sector SPDR and has greatly lagged its large-cap biotech peers.

French drugmaker Sanofi SA said it and U.S. firm Regeneron Pharmaceuticals have started recruiting patients for two new trials of their arthritis treatment sarilumab.

The reported earnings so far this quarter have been very good with about 67% of the constituents beating the analysts' estimates.

Regeneron Pharmaceuticals , a mid-sized biotechnology company, is a classic case of how FDA approval of a single drug can transform the fortunes of a biotech company.

Yet even after that hard-fought record, the S&P didn't stop rising, setting 11 more records, culminating in yesterday's new high of 1,634, almost 65 points higher than the index's March 28 close.

They currently have a $276.00 price target on the stock. Zacks' analyst wrote, "Regeneron Pharmaceuticals' first quarter 2013 adjusted earnings of $1.30 per share surpassed the Zacks Consensus Estimate of $1.06. Higher revenues, driven by strong sales of eye drug, Eylea, boosted earnings in the quarter.

Biotechnology companies that just a short time ago were viewed as takeover targets are now more likely to be buyers themselves after seeing their valuations soar on promising new drugs.

's stock had its "neutral" rating reiterated by Zacks in a research note issued to investors on Tuesday, AnalystRatingsNetwork.com reports.

Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Regeneron Pharmaceuticals, Inc.